C4 Therapeutics

🇺🇸United States
Ownership
-
Employees
145
Market Cap
$445.8M
Website
Introduction

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the na...

© Copyright 2024. All Rights Reserved by MedPath